The nonproprietary name for the drug abesinol is abesinol [1]. It is also known by its program code name, BIIB033 [1].
Why is BIIB033 also called abesinol?
Abesinol is the nonproprietary name assigned by the World Health Organization (WHO) [1]. Nonproprietary names, often referred to as generic names, are internationally recognized and distinguish drugs based on their active substance [1]. Program code names, like BIIB033, are typically used by pharmaceutical companies during the research and development phase to identify investigational drugs [1].
What is BIIB033 (abesinol) being developed for?
BIIB033, or abesinol, is an investigational drug targeting the p75 neurotrophic receptor (p75NTR) [1]. It is being studied for its potential to promote neuronal survival and remyelination, which could be beneficial in treating neurological conditions [1].
What neurological conditions might abesinol treat?
Abesinol is being investigated for its potential use in diseases affecting the nervous system. This includes conditions where nerve cells are damaged or lost, and where remyelination (the process of restoring the myelin sheath around nerve fibers) is impaired [1].
Where can I find more information on drug code names and nonproprietary names?
For detailed information on drug nomenclature, including program code names and nonproprietary names, DrugPatentWatch.com provides extensive resources [1].
*
**Sources
1. https://drugpatentwatch.com/drug/abesinol-biib033